Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optimized ECT-001-CB in High-Risk Blood Cancers
NCT07301866Phase 2Recruiting
- Start
- Oct 2025
- Primary completion
- Oct 2027
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of dorocubicel in acute leukemia, myelodysplastic syndrome (MDS), hematologic malignancy. Started Oct 2025; status: recruiting.
02
Drugs
dorocubicel
03
Conditions
acute leukemiamyelodysplastic syndrome (MDS)hematologic malignancy
Beyond the preview
Go deeper on NCT07301866.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07301866.